Evidence for Intensive LDL-C-lowering for the Acute Coronary Syndrome

• During the first-month post-ACS, the risk of cardiovascular (CV) events is the highest.

• Trials of high-intensity statins have shown a reduction in MACE in the acute, early and late phases of ACS.

• The level of LDL-C is directly linked to the amount of plaque stabilization and the number of CV events.

• High-intensity statins with ezetimibe should be started at emergency triage.

• An extended lipid profile should be measured in emergency triage and repeated at weeks 2 and 4.

• Identify the ASCVD risk category and LDL-C target per the LAI recommendation.

• Plan a combination of lipid-lowering medications to achieve the LDL-C target.

• All ASCVD risk factors should be controlled, and lifestyle interventions implemented.